Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Nov;50(Suppl 4):839–845. doi: 10.1136/ard.50.suppl_4.839

Raynaud's phenomenon: its relevance to scleroderma.

J J Belch 1
PMCID: PMC1033318  PMID: 1750795

Full text

PDF
839

Images in this article

840Image
on p.840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acute severe asthma. Lancet. 1981 Feb 7;1(8215):313–314. [PubMed] [Google Scholar]
  2. Belch J. J., Drury J., McLaughlin K., O'Dowd A., Anderson J., Sturrock R. D., Forbes C. D. Abnormal biochemical and cellular parameters in the blood of patients with Raynauds phenomenon. Scott Med J. 1987 Feb;32(1):12–14. doi: 10.1177/003693308703200106. [DOI] [PubMed] [Google Scholar]
  3. Belch J. J., McLaren M., Anderson J., Lowe G. D., Sturrock R. D., Capell H. A., Forbes C. D. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynauds syndrome. Prostaglandins Leukot Med. 1985 Jan;17(1):1–9. doi: 10.1016/0262-1746(85)90029-0. [DOI] [PubMed] [Google Scholar]
  4. Belch J. J., Zoma A. A., Richards I. M., McLaughlin K., Forbes C. D., Sturrock R. D. Vascular damage and factor-VIII-related antigen in the rheumatic diseases. Rheumatol Int. 1987;7(3):107–111. doi: 10.1007/BF00270462. [DOI] [PubMed] [Google Scholar]
  5. Bennett R., Bluestone R., Holt P. J., Bywaters E. G. Survival in scleroderma. Ann Rheum Dis. 1971 Nov;30(6):581–588. doi: 10.1136/ard.30.6.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bunker C. B., Lanigan S., Rustin M. H., Dowd P. M. The effects of topically applied hexyl nicotinate lotion on the cutaneous blood flow in patients with Raynaud's phenomenon. Br J Dermatol. 1988 Dec;119(6):771–776. doi: 10.1111/j.1365-2133.1988.tb03502.x. [DOI] [PubMed] [Google Scholar]
  7. Campbell P. M., LeRoy E. C. Raynaud phenomenon. Semin Arthritis Rheum. 1986 Nov;16(2):92–103. doi: 10.1016/0049-0172(86)90043-0. [DOI] [PubMed] [Google Scholar]
  8. Cardelli M. B., Kleinsmith D. M. Raynaud's phenomenon and disease. Med Clin North Am. 1989 Sep;73(5):1127–1141. doi: 10.1016/s0025-7125(16)30623-x. [DOI] [PubMed] [Google Scholar]
  9. Challenor V. F., Waller D. G., Hayward R. A., Griffin M. J., Roath O. S. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon. Angiology. 1989 Feb;40(2):122–128. doi: 10.1177/000331978904000207. [DOI] [PubMed] [Google Scholar]
  10. Clifford P. C., Martin M. F., Sheddon E. J., Kirby J. D., Baird R. N., Dieppe P. A. Treatment of vasospastic disease with prostaglandin E1. Br Med J. 1980 Oct 18;281(6247):1031–1034. doi: 10.1136/bmj.281.6247.1031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Coffman J. D., Clement D. L., Creager M. A., Dormandy J. A., Janssens M. M., McKendry R. J., Murray G. D., Nielsen S. L. International study of ketanserin in Raynaud's phenomenon. Am J Med. 1989 Sep;87(3):264–268. doi: 10.1016/s0002-9343(89)80148-2. [DOI] [PubMed] [Google Scholar]
  12. Cruz M., Mejia G., Lavalle C., Cortes J. J., Reyes P. A. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon. Clin Rheumatol. 1988 Mar;7(1):80–86. doi: 10.1007/BF02284061. [DOI] [PubMed] [Google Scholar]
  13. DiGiacomo R. A., Kremer J. M., Shah D. M. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158–164. doi: 10.1016/0002-9343(89)90261-1. [DOI] [PubMed] [Google Scholar]
  14. Duffy C. M., Laxer R. M., Lee P., Ramsay C., Fritzler M., Silverman E. D. Raynaud syndrome in childhood. J Pediatr. 1989 Jan;114(1):73–78. doi: 10.1016/s0022-3476(89)80604-3. [DOI] [PubMed] [Google Scholar]
  15. Fitzgerald O., Hess E. V., O'Connor G. T., Spencer-Green G. Prospective study of the evolution of Raynaud's phenomenon. Am J Med. 1988 Apr;84(4):718–726. doi: 10.1016/0002-9343(88)90109-x. [DOI] [PubMed] [Google Scholar]
  16. Franks A. G., Jr Topical glyceryl trinitrate as adjunctive treatment in Raynaud's disease. Lancet. 1982 Jan 9;1(8263):76–77. doi: 10.1016/s0140-6736(82)90215-x. [DOI] [PubMed] [Google Scholar]
  17. Friedman E. I., Taylor L. M., Jr, Porter J. M. Late-onset Raynaud's syndrome: diagnostic and therapeutic considerations. Geriatrics. 1988 Dec;43(12):59-63, 67-70. [PubMed] [Google Scholar]
  18. GIFFORD R. W., Jr, HINES E. A., Jr Raynaud's disease among women and girls. Circulation. 1957 Dec;16(6):1012–1021. doi: 10.1161/01.cir.16.6.1012. [DOI] [PubMed] [Google Scholar]
  19. Gabrielli A., Montroni M., Rupoli S., Caniglia M. L., DeLustro F., Danieli G. A retrospective study of antibodies against basement membrane antigens (type IV collagen and laminin) in patients with primary and secondary Raynaud's phenomenon. Arthritis Rheum. 1988 Nov;31(11):1432–1436. doi: 10.1002/art.1780311114. [DOI] [PubMed] [Google Scholar]
  20. Gerbracht D. D., Steen V. D., Ziegler G. L., Medsger T. A., Jr, Rodnan G. P. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum. 1985 Jan;28(1):87–92. doi: 10.1002/art.1780280114. [DOI] [PubMed] [Google Scholar]
  21. Goldman J. A. Anticentromere antibody in patients without CREST and scleroderma: association with active digital vasculitis, rheumatic and connective tissue disease. Ann Rheum Dis. 1989 Sep;48(9):771–775. doi: 10.1136/ard.48.9.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hunt T. K. Disorders of wound healing. World J Surg. 1980 May;4(3):271–277. doi: 10.1007/BF02393382. [DOI] [PubMed] [Google Scholar]
  23. Kahaleh M. B., Osborn I., LeRoy E. C. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon. Ann Intern Med. 1981 Apr;94(4 Pt 1):482–484. doi: 10.7326/0003-4819-94-4-482. [DOI] [PubMed] [Google Scholar]
  24. Kahaleh M. B., Sherer G. K., LeRoy E. C. Endothelial injury in scleroderma. J Exp Med. 1979 Jun 1;149(6):1326–1335. doi: 10.1084/jem.149.6.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kahan A., Devaux J. Y., Amor B., Menkès C. J., Weber S., Nitenberg A., Venot A., Guérin F., Degeorges M., Roucayrol J. C. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med. 1986 May 29;314(22):1397–1402. doi: 10.1056/NEJM198605293142201. [DOI] [PubMed] [Google Scholar]
  26. Kallenberg C. G. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am. 1990 Feb;16(1):11–30. [PubMed] [Google Scholar]
  27. Kallenberg C. G., Wouda A. A., Hoet M. H., van Venrooij W. J. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis. 1988 Aug;47(8):634–641. doi: 10.1136/ard.47.8.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kallenberg C. G., Wouda A. A., The T. H. Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med. 1980 Nov;69(5):675–680. doi: 10.1016/0002-9343(80)90417-9. [DOI] [PubMed] [Google Scholar]
  29. Klimiuk P. S., Grennan A., Weinkove C., Jayson M. I. Platelet serotonin in systemic sclerosis. Ann Rheum Dis. 1989 Jul;48(7):586–589. doi: 10.1136/ard.48.7.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Maricq H. R., Harper F. E., Khan M. M., Tan E. M., LeRoy E. C. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol. 1983 Jul-Sep;1(3):195–205. [PubMed] [Google Scholar]
  31. Maricq H. R., Weinberger A. B., LeRoy E. C. Early detection of scleroderma-spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. J Rheumatol. 1982 Mar-Apr;9(2):289–291. [PubMed] [Google Scholar]
  32. Maricq H. R., Weinrich M. C., Keil J. E., LeRoy E. C. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. J Chronic Dis. 1986;39(6):423–427. doi: 10.1016/0021-9681(86)90109-8. [DOI] [PubMed] [Google Scholar]
  33. Maricq H. R., Weinrich M. C., Keil J. E., Smith E. A., Harper F. E., Nussbaum A. I., LeRoy E. C., McGregor A. R., Diat F., Rosal E. J. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum. 1989 Aug;32(8):998–1006. doi: 10.1002/anr.1780320809. [DOI] [PubMed] [Google Scholar]
  34. Miyazaki S., Miura K., Kasai Y., Abe K., Yoshinaga K. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):310–311. doi: 10.1136/bmj.284.6312.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Niinikoski J., Hunt T. K., Dunphy J. E. Oxygen supply in healing tissue. Am J Surg. 1972 Mar;123(3):247–252. doi: 10.1016/0002-9610(72)90277-2. [DOI] [PubMed] [Google Scholar]
  36. Nilsen K. H. Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon. Br Med J. 1979 Jan 6;1(6155):20–21. doi: 10.1136/bmj.1.6155.20-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Olsen N., Nielsen S. L. Prevalence of primary Raynaud phenomena in young females. Scand J Clin Lab Invest. 1978 Dec;38(8):761–764. doi: 10.1080/00365517809104884. [DOI] [PubMed] [Google Scholar]
  38. Pal B., Gibson C., Passmore J., Griffiths I. D., Dick W. C. A study of headaches and migraine in Sjögren's syndrome and other rheumatic disorders. Ann Rheum Dis. 1989 Apr;48(4):312–316. doi: 10.1136/ard.48.4.312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Porter J. M., Rivers S. P., Anderson C. J., Baur G. M. Evaluation and management of patients with Raynaud's syndrome. Am J Surg. 1981 Aug;142(2):183–189. doi: 10.1016/0002-9610(81)90272-5. [DOI] [PubMed] [Google Scholar]
  40. Rademaker M., Cooke E. D., Almond N. E., Beacham J. A., Smith R. E., Mant T. G., Kirby J. D. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ. 1989 Mar 4;298(6673):561–564. doi: 10.1136/bmj.298.6673.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Rodeheffer R. J., Rommer J. A., Wigley F., Smith C. R. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med. 1983 Apr 14;308(15):880–883. doi: 10.1056/NEJM198304143081507. [DOI] [PubMed] [Google Scholar]
  42. Rodnan G. P., Myerowitz R. L., Justh G. O. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980 Nov;59(6):393–408. doi: 10.1097/00005792-198011000-00001. [DOI] [PubMed] [Google Scholar]
  43. Seibold J. R., Harris J. N. Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon. J Rheumatol. 1985 Feb;12(1):99–103. [PubMed] [Google Scholar]
  44. Silverstein J. L., Steen V. D., Medsger T. A., Jr, Falanga V. Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch Dermatol. 1988 Sep;124(9):1379–1382. [PubMed] [Google Scholar]
  45. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  46. TUFFANELLI D. L., WINKELMANN R. K. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol. 1961 Sep;84:359–371. doi: 10.1001/archderm.1961.01580150005001. [DOI] [PubMed] [Google Scholar]
  47. Yardumian D. A., Isenberg D. A., Rustin M., Belcher G., Snaith M. L., Dowd P. M., Machin S. J. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Br J Rheumatol. 1988 Jun;27(3):220–226. doi: 10.1093/rheumatology/27.3.220. [DOI] [PubMed] [Google Scholar]
  48. Zahavi J., Hamilton W. A., O'Reilly M. J., Leyton J., Cotton L. T., Kakkar V. V. Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res. 1980 Jul 1;19(1-2):85–93. doi: 10.1016/0049-3848(80)90406-5. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES